Australia - englanti - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); latanoprost, quantity: 0.05 mg/ml - eye drops, solution - excipient ingredients: purified water; benzalkonium chloride; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate; hydrochloric acid; sodium chloride - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanoprost/timolol (50 microgram/ml/5 mg/ml) eye drops should not be used to initiate therapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium hydroxide; sodium chloride; hydrochloric acid; disodium edetate; purified water - indications as at 23 march 1999: betoptic 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoptic eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - proxymetacaine hydrochloride, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: glycerol; benzalkonium chloride; hydrochloric acid; purified water; sodium hydroxide - indications as at 13 jan 2005 : alcaine eye drops are indicated for procedures in which a rapid and short-acting topical ophthalmic anaesthetic is indicated such as in cataract surgery and suture removal from the cornea, and in tonometry, gonioscopy, removal of corneal foreign bodies, conjunctival scraping for diagnostic purposes, and other short corneal and conjunctival procedures.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - gentamicin sulfate, quantity: 3 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: polyvinyl alcohol; dibasic sodium phosphate heptahydrate; sodium chloride; disodium edetate; benzalkonium chloride; sodium hydroxide; purified water; hydrochloric acid - gentopic eye drops are indicated in the topical treatment of infections of the external eye and its adnexa caused by susceptible bacteria. such infections include conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivits, acute meibomianitis and dacryocystitis.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - atropine sulfate monohydrate, quantity: 9.9737 mg/ml - eye drops, solution - excipient ingredients: boric acid; disodium edetate; benzalkonium chloride; hypromellose; water for injections - indications as at 06 august 1999: atropt eye drops are indicated where it is necessary to dilate the pupil and paralyse accomodation.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atropine sulfate monohydrate, quantity: 0.1027 mg/ml (equivalent: atropine sulfate, qty 0.1 mg/ml) - eye drops, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - eikance 0.01% is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 d per year.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

pilocarpine nitrate -

Kenia - englanti - Pharmacy and Poisons Board

aurolab sivagangai main road veerapanjan madurai 625 020 - pilocarpine nitrate usp 2% w/v - eye drops - pilocarpine nitrate usp 2% w/v - ophthalmological antiglaucoma preparations and

Australia - englanti - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - oxybuprocaine hydrochloride, quantity: 4 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid - to produce local anaesthesia in the eye.